RadNet, Inc. (RDNT) Stock: Q4 2025 Revenue and EBITDA Hit Record Highs, Digital Health Surges 48%

TLDR

• RDNT Q4 revenue jumps 14.8%, driven by imaging center growth and efficiency.
• Digital Health soars 48%, with AI solutions fueling subscription stability.
• MRI, CT, PET/CT volumes climb double digits, same-center growth strong.
• 2026 guidance: Imaging revenue +17–19%, EBITDA +18–22%, FCF up 29–41%.
• Gleamer acquisition expands AI offerings; FDA clearances planned in 2026.

RadNet, Inc. (RDNT) closed at $69.81, down 3.16% (-$2.28), while pre-market trading shows a rebound to $74.50, up 6.72%.

RadNet, Inc., RDNT
RDNT posted record revenue of $547.7 million in Q4 2025, up 14.8% from $477.1 million. Adjusted EBITDA reached $87.7 million, representing a 16.9% increase from the previous year. Strong procedural volumes and operational efficiencies supported the quarterly performance across its Imaging Center segment.

Digital Health revenue rose sharply to $27.9 million, marking a 48.2% gain from $18.9 million in Q4 2024. Adjusted EBITDA in Digital Health increased to $4.9 million, an 8.9% rise year-over-year. The company maintained a Total Company Adjusted EBITDA margin of 16%, up 29 basis points from last year.

Adjusted earnings per share remained stable at $0.23, compared with $0.24 in Q4 2024, excluding one-time items. Total Company net loss, unadjusted for one-time items, was $0.6 million versus net income of $5.3 million in the prior year. Weighted average diluted shares outstanding grew slightly to 76.6 million from 75.5 million in Q4 2024.

Imaging Center Segment Shows Strong Procedural Growth

Aggregate advanced imaging procedures increased 14.1%, while same-center procedures rose 9.6% over Q4 2024. MRI volume expanded 15.8%, CT volume grew 10.3%, and PET/CT surged 28.3% overall. Same-center volumes rose 11.4% for MRI, 6.3% for CT, and 14.3% for PET/CT, indicating strong operational consistency.

Total full-year 2025 Imaging Center revenue contributed significantly to overall growth, supporting the $2.04 billion annual revenue. Adjusted EBITDA for the year reached $300.2 million, a 7.4% increase from 2024. New center openings, tuck-in acquisitions, and improved patient throughput drove revenue and EBITDA growth.

RadNet anticipates 2026 Imaging Center revenue growth of 17%-19% and adjusted EBITDA growth of 18%-22%. Free cash flow is projected to grow 29%-41% over 2025 levels. The company continues to focus on efficiency, capacity improvements, and favorable reimbursement strategies.

Digital Health Segment Surges Amid AI Expansion

Digital Health revenue grew 41.1% in 2025 to $92.7 million, supported by recurring revenue streams. Adjusted EBITDA increased slightly to $15.5 million, reflecting ongoing investments in clinical AI and workflow technology. Annual Recurring Revenue (ARR) represented 81.3% of 2025 segment revenue, showing strong subscription stability.

RadNet acquired Gleamer SAS in 2026, expanding Digital Health offerings in AI-powered clinical solutions. The company plans multiple FDA clearances in mammography, lung, prostate, thyroid, and musculoskeletal areas. Revenue contribution from Imaging Center segment to Digital Health is expected to decline from 45% to 33% in 2026, reflecting broader commercialization.

For 2026, Digital Health guidance projects revenue of $135-$145 million, with adjusted EBITDA before non-capitalized R&D of $10-$12 million. Free cash flow, after accounting for non-capitalized R&D, is expected at negative $17-$19 million. Significant infrastructure and team investments aim to support scalable growth and industry-wide adoption of advanced solutions.

The post  RadNet, Inc. (RDNT) Stock: Q4 2025 Revenue and EBITDA Hit Record Highs, Digital Health Surges 48% appeared first on CoinCentral.